论文部分内容阅读
急性心肌梗死后尽早实施再灌注治疗是临床首选治疗措施。静脉溶栓具有简便、经济、易操作等特点，其能使闭塞冠状动脉再通，使缺血心肌及时再灌注。在生物工程技术的应用下，新型溶栓药物使血管再通速度更快，操作更方便，并发症减少。同时，新型溶栓药物的应用，不仅降低了患者的病死率，还提高了患者的生存质量。目前，很多溶栓药物处于研发阶段，或期待临床试验证实其疗效，为进一步的研究指明方向。“,”Reperfusion therapy as soon as possible after acute myocardial infarction is the preferred clini-cal treatment.Intravenous thrombolysis is featured with simple,economic and easy to operate,and can make the occluded coronary artery recanalization, make the ischemic myocardial reperfusion in time.Under the application of biological engineering technology,the new thrombolytic drugs make recanalization faster,more convenient to operate,with reduced complications.The application of new type of thrombolytic drugs,not only reduces the mortality,but also improves the survival quality of the patients.At present,a lot of thrombolytic drugs are in the research and development phase or expected to prove the efficacy by clinical trials , which indicates the direction for further research.